“Abirataj hydrochloride Capsule is indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine. Abirataj hydrochloride should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects. Abirataj hydrochloride is not indicated for treatment of biliary cirrhosis".
“Take Abirataj hydrochloride Capsuleexactly as directed by your doctor. Do not take more or less than instructed by your doctor. Patients should be directed to take trientine hydrochloride Capsuleon an empty stomach, at least 1 hour before meals or 2 hours after meals and at least 1 hour apart from any other drug, food, or milk. The capsules should be swallowed whole with water and should not be opened or chewed".
“Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose".
“Ask your doctor before using a vitamin or mineral supplement, and use only the type your doctor recommends. Some minerals can make it harder for your body to absorb Abitataj".
“Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat".
“Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose".
Abirataj is indicated in combination with prednisone for the treatment of patients with • Metastatic castration-resistant prostate cancer (CRPC) • Metastatic high-risk castration-sensitive prostate cancer (CSPC)
read moreRecommended Dose For Metastatic CRPC
The recommended dose of abirataj is 1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily with prednisone 5 mg orally twice daily.
Like all medicines, this medicine can cause side effects, although not everybody gets them.. Stop taking Abiraterone Acetate Tablet and see a doctor immediately if you notice any of the following side effects.
read moreDrugs That Inhibit Or Induce CYP3A4 Enzymes
In a dedicated drug interaction trial, co-administration of rifampin, a strong CYP3A4 inducer, decreased exposure of abiraterone by 55%.
Abirataj may cause hypertension, hypokalemia, and fluid retention increased mineralocorticoid levels resulting from CYP17 inhibition.Monitor patients for hypertension, hypokalemia, and fluid retention at least once a month.
read moreMechanism Of Action
Abiraterone acetate (Abirataj) is converted in vivo to abiraterone, an androgen biosynthesis inhibitor, that inhibits 17 α-hydroxylase/C17,20-lyase (CYP17).